Tackling intra- and inter-tumor heterogeneity to combat triple negative breast cancer.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Frontiers in Bioscience

• Publication date

  2017-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2741/4558PMID 28410132
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00

  2016cited by this paper
• Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.

  2016cited by this paper
• Biology and Management of Patients With Triple-Negative Breast Cancer.

  2016cited by this paper
• Centrosome amplification induces high grade features and is prognostic of worse outcomes in breast cancer

  2016cited by this paper
• The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression–Based Meta-Analysis

  2016cited by this paper
• Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

  2016cited by this paper
• Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection

  2016cited by this paper
• Transition to resistance: An unexpected role of the EMT in cancer chemoresistance

  2016cited by this paper
• MUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice

  2016cited by this paper
• Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting

  2016cited by this paper
• Adaptive Randomization of Neratinib in Early Breast Cancer.

  2016cited by this paper
• Targeting Notch degradation system provides promise for breast cancer therapeutics.

  2016cited by this paper
• Adaptive Randomization of Neratinib in Early Breast Cancer.

  2016cited by this paper
• Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

  2016influential reference
• Role of the androgen receptor in triple-negative breast cancer.

  2016cited by this paper
• Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors.

  2015cited by this paper
• Expression of FGFR1 is an independent prognostic factor in triple-negative breast cancer

  2015cited by this paper
• Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.

  2015cited by this paper
• Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models

  2015cited by this paper
• Intratumoral heterogeneity: Clonal cooperation in epithelial-to-mesenchymal transition and metastasis

  2015cited by this paper
• Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?

  2015cited by this paper
• WEE1 Kinase As a Target for Cancer Therapy.

  2015cited by this paper
• Histone deacetylase inhibitors in castration-resistant prostate cancer: molecular mechanism of action and recent clinical trials

  2015cited by this paper
• The fate of chemoresistance in triple negative breast cancer (TNBC)

  2015cited by this paper
• Turning the headlights on novel cancer biomarkers: Inspection of mechanics underlying intratumor heterogeneity.

  2015cited by this paper
• Rampant centrosome amplification underlies more aggressive disease course of triple negative breast cancers

  2015cited by this paper
• Histone deacetylase inhibitor entinostat in combination with a retinoid downregulates HER2 and reduces the tumor initiating cell population in aromatase inhibitor-resistant breast cancer

  2015cited by this paper
• Development of anticancer agents targeting the Wnt/β-catenin signaling.

  2015cited by this paper
• Associate editor: B. TeicherTargeting breast cancer through its microenvironment: Current status of preclinical and clinical research in finding relevant targets

  2015cited by this paper
• Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update

  2015cited by this paper
• The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours

  2015cited by this paper
• The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients

  2015cited by this paper
• Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus White Women and the Association of Racial Differences With Tumor Recurrence.

  2015cited by this paper
• Targeting Breast Cancer with CDK Inhibitors

  2015cited by this paper
• Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy and analysis of survival outcomes.

  2015cited by this paper
• The association between chronic pain and obesity

  2015cited by this paper
• Targeting Oncogenic Mutant p53 for Cancer Therapy

  2015cited by this paper
• How to be good at being bad: centrosome amplification and mitotic propensity drive intratumoral heterogeneity

  2015cited by this paper
• PI3K isoform-selective inhibitors: next-generation targeted cancer therapies

  2015cited by this paper
• Aldehyde Dehydrogenase 1 (ALDH1) Is a Potential Marker for Cancer Stem Cells in Embryonal Rhabdomyosarcoma

  2015cited by this paper
• Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State

  2015cited by this paper
• Targeting matrix metalloproteinases in cancer: Bringing new life to old ideas

  2015cited by this paper
• Triple-negative breast cancer in African-American women: disparities versus biology

  2015cited by this paper
• PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors

  2014cited by this paper
• Comparative Proteome Analysis Revealing an 11-Protein Signature for Aggressive Triple-Negative Breast Cancer

  2014cited by this paper
• Measures of outcome in metastatic breast cancer: insights from a real-world scenario.

  2014cited by this paper
• Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer

  2014cited by this paper
• The latest progress in research on triple negative breast cancer (TNBC): risk factors, possible therapeutic targets and prognostic markers.

  2014cited by this paper
• Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers

  2014cited by this paper
• Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry.

  2014cited by this paper
• Triple-negative Breast Carcinoma in African American and Caucasian Women: Clinicopathology, Immunomarkers, and Outcome

  2014cited by this paper
• Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer

  2014cited by this paper
• Comparison of recurrent and nonrecurrent breast cancer patients undergoing AE37 peptide vaccine therapy.

  2014cited by this paper
• Predicting response and survival in chemotherapy-treated triple-negative breast cancer

  2014cited by this paper
• Basal-like and triple-negative breast cancers: searching for positives among many negatives.

  2014cited by this paper
• Assessing adaptation of the cancer kinome in response to targeted therapies.

  2014cited by this paper
• Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.

  2014cited by this paper
• Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer.

  2014cited by this paper
• First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer

  2014cited by this paper
• Expression of Topoisomerase II-&agr; in Triple Negative Breast Cancer

  2014cited by this paper
• Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†.

  2014cited by this paper
• Therapeutic modulation of Notch signalling — are we there yet?

  2014cited by this paper
• Tackling the cancer stem cells — what challenges do they pose?

  2014cited by this paper
• Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide

  2014cited by this paper
• Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators

  2014cited by this paper
• Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes

  2013cited by this paper
• Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer.

  2013cited by this paper
• Expression of VEGF and Semaphorin Genes Define Subgroups of Triple Negative Breast Cancer

  2013cited by this paper
• Emerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities for an innovative approach

  2013cited by this paper
• Metabolic interaction between cancer cells and stromal cells according to breast cancer molecular subtype

  2013cited by this paper
• Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer

  2013cited by this paper
• Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients

  2013cited by this paper
• PTEN Loss Increases PD-L1 Protein Expression and Affects the Correlation between PD-L1 Expression and Clinical Parameters in Colorectal Cancer

  2013cited by this paper
• Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8.

  2013cited by this paper
• Design, Synthesis, and Biological Evaluation of an Allosteric Inhibitor of HSET that Targets Cancer Cells with Supernumerary Centrosomes

  2013cited by this paper
• Mechanisms of chemoresistance in cancer stem cells

  2013cited by this paper
• Molecular Phenotypes in Triple Negative Breast Cancer from African American Patients Suggest Targets for Therapy

  2013cited by this paper
• Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation.

  2013cited by this paper
• A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours.

  2013cited by this paper
• MUC1 is expressed at high frequency in early-stage basal-like triple-negative breast cancer.

  2013cited by this paper
• Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer.

  2013cited by this paper
• Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer

  2013cited by this paper
• Molecular characterization of basal-like and non-basal-like triple-negative breast cancer.

  2013cited by this paper
• Targeting mutant p53 in human tumors.

  2012cited by this paper
• Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents.

  2012cited by this paper
• First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.

  2012cited by this paper
• The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

  2012cited by this paper
• Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1.

  2012cited by this paper
• GF-15, a novel inhibitor of centrosomal clustering, suppresses tumor cell growth in vitro and in vivo.

  2012cited by this paper
• Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple‐negative and basal‐like breast cancers

  2012cited by this paper
• The clonal and mutational evolution spectrum of primary triple-negative breast cancers

  2012cited by this paper
• Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer.

  2012cited by this paper
• Triple-negative breast cancer: epidemiological considerations and recommendations.

  2012cited by this paper
• Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro

  2012cited by this paper
• Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat

  2012cited by this paper
• Eribulin mesylate in the treatment of metastatic breast cancer

  2012cited by this paper
• PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition.

  2012cited by this paper
• IGF-1 and BRCA1 signalling pathways in familial cancer.

  2012cited by this paper
• The insulin and insulin-like growth factor receptor family in neoplasia: an update

  2012cited by this paper
• Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

  2012cited by this paper

• Clinical complete response achieved in patients with breast cancer liver metastasis after personalized treatment: a case report and literature review

  2026cites this paper
• Targeting the Tumor Microenvironment in Triple-Negative Breast Cancer: Emerging Roles of Monoclonal Antibodies and Immune Modulation

  2026cites this paper
• Advances in targeted therapy for triple-negative breast cancer: a review of key antigens and recent advances

  2025cites this paper
• Wnt signaling promotes inflammation and EMT-associated gene expression in mesenchymal TNBC

  2025cites this paper
• Adaptive Control of Tumor Growth

  2024cites this paper
• Phenotypic heterogeneity drives differential disease outcome in a mouse model of triple negative breast cancer

  2023cites this paper
• Racial Disparities in Breast Cancer Treatments and Adverse Events in the SEER-Medicare Data

  2023cites this paper
• Racial Disparity in Quadruple Negative Breast Cancer: Aggressive Biology and Potential Therapeutic Targeting and Prevention

  2022cites this paper
• TH1902, a new docetaxel‐peptide conjugate for the treatment of sortilin‐positive triple‐negative breast cancer

  2021cites this paper
• Target Heterogeneity in Oncology: The Best Predictor for Differential Response to Radioligand Therapy in Neuroendocrine Tumors and Prostate Cancer

  2021cites this paper
• QNBC Is Associated with High Genomic Instability Characterized by Copy Number Alterations and miRNA Deregulation

  2021cites this paper
• Quadruple-negative breast cancer: novel implications for a new disease

  2020cites this paper
• Single-cell RNA-seq data reveals TNBC tumor heterogeneity through characterizing subclone compositions and proportions

  2019cites this paper
• Tumor Site-Dependent Transport Properties Determine Nanotherapeutics Delivery and Its Efficacy

  2019cites this paper
• Not Everyone Fits the Mold: Intratumor and Intertumor Heterogeneity and Innovative Cancer Drug Design and Development

  2018cites this paper
• Targeting PLK 1 overcomes TDM 1 resistance via CDK 1-dependent phosphorylation and inactivation of Bcl-2 / xL in HER 2-positive breast cancer

  2018cites this paper
• Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer

  2018cites this paper
• A novel theranostics nanoparticles pGGA-PTX / SPION with bifunction of diagnosis and treatment

  2018cites this paper
• Panoptic Overview of Triple-Negative Breast Cancer in Nigeria: Current Challenges and Promising Global Initiatives

  2018cites this paper